Get the Stockscreener App
57.25
1.22%
0.69
Tarsus Pharmaceuticals Inc stock is traded at $57.25, with a volume of 594.29K.
It is up +1.22% in the last 24 hours and up +35.21% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$56.56
Open:
$56.69
24h Volume:
594.29K
Relative Volume:
0.99
Market Cap:
$2.42B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-12.34
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+5.61%
1M Performance:
+35.21%
6M Performance:
+19.67%
1Y Performance:
+126.20%
1-Day Range:
$55.34
$57.60
1-Week Range:
$53.15
$57.60
52-Week Range:
$25.19
$57.60
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
57.25 | 2.31B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Top 2 Health Care Stocks That May Fall Off A Cliff In August - inkl
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair - MSN
Combining price and volume data for Tarsus Pharmaceuticals Inc.Market Risk Summary & Proven Capital Preservation Methods - Newser
Visualizing Tarsus Pharmaceuticals Inc. stock with heatmapsQuarterly Portfolio Summary & Growth-Oriented Investment Plans - Newser
Applying Elliott Wave Theory to Tarsus Pharmaceuticals Inc.July 2025 Trade Ideas & Technical Entry and Exit Alerts - Newser
Evaluating Tarsus Pharmaceuticals Inc. with trendline analysisQuarterly Profit Review & Entry Point Confirmation Signals - Newser
Can machine learning forecast Tarsus Pharmaceuticals Inc. recoveryTrade Exit Summary & Reliable Intraday Trade Alerts - Newser
Top Risks to Consider Before Buying Tarsus Pharmaceuticals Inc. StockJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Why Tarsus Pharmaceuticals Inc. is moving todayPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - Newser
How Tarsus Pharmaceuticals Inc. stock performs during market volatilityInflation Watch & Verified Stock Trade Ideas - Newser
Volume spikes in Tarsus Pharmaceuticals Inc. stock – what they meanJuly 2025 Momentum & Verified Momentum Watchlists - Newser
Can technical indicators confirm Tarsus Pharmaceuticals Inc.’s reversal2025 Dividend Review & Safe Capital Investment Plans - Newser
Using Python tools to backtest Tarsus Pharmaceuticals Inc. strategies - Newser
Reversal indicators forming on Tarsus Pharmaceuticals Inc. stockQuarterly Trade Summary & Weekly Top Gainers Trade List - Newser
How to build a custom watchlist for Tarsus Pharmaceuticals Inc.Weekly Volume Report & AI Driven Price Predictions - Newser
How hedge fund analytics apply to Tarsus Pharmaceuticals Inc. stock2025 Analyst Calls & Fast Moving Market Watchlists - Newser
Tools to assess Tarsus Pharmaceuticals Inc.’s risk profileWeekly Stock Summary & Community Driven Trade Alerts - Newser
Tarsus Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Trend Summary & High Accuracy Swing Trade Signals - Newser
Published on: 2025-08-14 04:24:26 - beatles.ru
Why Tarsus Pharmaceuticals Inc. stock attracts strong analyst attentionMarket Trend Summary & Accurate Trade Setup Notifications - Newser
Pattern recognition hints at Tarsus Pharmaceuticals Inc. upsideWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Grading 2 Pharma Stocks That Are Heating Up as Large-Cap Rivals Falter - TheStreet Pro
Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87 - MSN
Tarsus Pharmaceuticals Q2 2025: Key Contradictions on XDEMVY's Market Potential, Discount Strategies, and Seasonal Sales Trends - AInvest
Published on: 2025-08-10 23:25:21 - Newser
Detecting support and resistance levels for Tarsus Pharmaceuticals Inc.Market Timing Strategy with Technical Filters - Newser
Tarsus Pharmaceuticals’ Earnings Call Highlights XDEMVY Success - TipRanks
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals shares fall 7.01% after-hours following Q2 2025 earnings call. - AInvest
Tarsus Pharmaceuticals Reports Record Q2 Net Sales of $102.66M, Exceeding Consensus - AInvest
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84 - 富途牛牛
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating - TipRanks
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Envestnet Asset Management Inc. - Defense World
Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum - MSN
Tarsus Pharmaceuticals: Scaling a High-Growth Eye Care Platform with a Diversified Pipeline and Strong Commercial Execution - AInvest
Tarsus Pharmaceuticals Sees 95,000-100,000 Bottles Target for Q3 2025 Amid Record-Breaking Sales - AInvest
Tarsus Pharmaceuticals Reports Record Sales Growth - TipRanks
Transcript : Tarsus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Tarsus 2025 Q2 Earnings Loss Narrows as Revenue Surges 151.5% - AInvest
Tarsus Pharmaceuticals : Second Quarter 2025 Earnings Presentation - MarketScreener
Tarsus Pharmaceuticals Q2 revenue beats expectations - MarketScreener
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Globe and Mail
Tarsus Pharmaceuticals Reports Record $102.7 Million in Quarterly Net Product Sales of XDEMVY, a 152% Increase Year Over Year - Quiver Quantitative
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewswire
Published on: 2025-08-04 16:33:09 - beatles.ru
How does Tarsus Pharmaceuticals Inc. compare to its industry peersProven strategies for superior portfolio growth - Jammu Links News
What are the technical indicators suggesting about Tarsus Pharmaceuticals Inc.Maximize gains with timely market signals - Jammu Links News
Is Tarsus Pharmaceuticals Inc. stock overvalued or undervaluedRapid growth opportunities - Jammu Links News
Why is Tarsus Pharmaceuticals Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - Jammu Links News
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):